• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Friday, September 22, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Informed consent forms for lung cancer clinical trials may be a barrier to informed trial participation

Bioengineer by Bioengineer
August 9, 2022
in Cancer
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

(Vienna, August 9, 2022, 10:10 a.m. CEST)— Informed consent forms are overwhelming for patients. They are written at a level that is too high for most patients, thus possibly impeding real informed consents, according to a report given today at the IASLC World Conference on Lung Cancer in Vienna. 

Bellinda King-Kallimanis, PhD., Director of Patient-Focused Research at LUNGevity Foundation in Bethesda, Md

Credit: Bellinda King-Kallimanis, PhD., Director of Patient-Focused Research at LUNGevity Foundation in Bethesda, Md

(Vienna, August 9, 2022, 10:10 a.m. CEST)— Informed consent forms are overwhelming for patients. They are written at a level that is too high for most patients, thus possibly impeding real informed consents, according to a report given today at the IASLC World Conference on Lung Cancer in Vienna. 

The purpose of the informed consent form (ICF) is to outline risks and benefits of an interventional clinical trial to a patient. But most ICFs are written using scientific jargon, are long, and include extraneous information not pertinent to the patient (e.g., legalities of trial participation), according to Bellinda King-Kallimanis, PhD., Director of Patient-Focused Research at LUNGevity Foundation in Bethesda, Md. 

King-Kallimanis and her colleagues conducted a multi-step project involving patients and caregivers, trialists, regulators, and clinical trial sponsors to streamline the informed consent process. After a thorough analysis of their findings some key challenges emerged along with ideas for improving ICFs. One possible resolution strategy that patients supported would be to create  a tri-fold template summarizing key points of the ICF that are relevant to patients, which can be used as addendum to the ICF. 

The first step included an audit of 20 ICFs guided by U.S. Department of Health and Human Services regulations for the protection of human subjects in research. The second step included focus groups and in-depth interviews with nine patients living with lung cancer to learn what information was critical when considering participation in a clinical trial using a hypothetical ICF to guide the conversation.  

The 20 ICFs reviewed were from phases 1, 2, and 3 clinical trials covering predominantly non-small cell lung cancer — 60% were global trials. Most of the legally required CFR topics were covered. However,  forms were long, ranging between 15-34 pages, with an average length of  21 pages. Readability varied by section but the average reading level across section was 10th grade, whereas average US reading level is 8th grade.  

The second step of the study was the qualitative research component in which participants were presented with a hypothetical ICF. Participants generally noted feeling “overwhelmed” by the hypothetical ICF. It was noted that “a lot of information was good” but that important information for deciding whether to participate was often too hard to find. When asked the intent of the forms, one participant noted “to cover their butts”. The idea of an addendum that provides a summary with reference to page numbers in the ICF for more details was well received by participants. The next phase of this work is to develop a tri-fold addendum and test it with patients and caregivers.  

“While ICFs place greatest emphasis on trial procedures and risks, variations in ICF architecture and readability make it difficult for patients to make an informed decision to participate in a clinical trial,” King-Kallimanis reported. “Our study implications extend beyond lung cancer, highlighting key areas for improvements to the ICFs and providing a clear roadmap for developing a patient-centric addendum for ICFs in all cancer clinical trials.” 

About the WCLC: 

The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc2022.iaslc.org/. 



Share12Tweet8Share2ShareShareShare2

Related Posts

Immune Cells

Australian research leads to clinical trial for rare women’s cancers

September 22, 2023
Annika Wylie

Cancer Prevention and Research Institute of Texas awards $2 million grant to SMU

September 21, 2023

Rewiring tumor mitochondria enhances the immune system’s ability to recognize and fight cancer

September 21, 2023

Combination of cancer vaccine and T cell therapy benefits patients with advanced ovarian cancer

September 21, 2023

POPULAR NEWS

  • blank

    Microbe Computers

    58 shares
    Share 23 Tweet 15
  • University of South Florida scientist: Barnacles may help reveal location of lost Malaysia Airlines flight MH370

    46 shares
    Share 18 Tweet 12
  • Lithuanian invention at the forefront of solar technology breakthrough

    41 shares
    Share 16 Tweet 10
  • A pioneering study from Politecnico di Milano sheds light on one of the still poorly understood aspects of cancer

    34 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

One-stop implementation from signal detection to processing

Australian research leads to clinical trial for rare women’s cancers

Ochsner offers tuition assistance to aspiring nurses and doctors

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 57 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In